

Boris Cvek

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1551356/boris-cvek-publications-by-year.pdf>

Version: 2022-10-05

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25
papers

980
citations

12
h-index

30
g-index

30
ext. papers

1,081
ext. citations

7.1
avg. IF

4.33
L-index

#	Paper	IF	Citations
25	Promoting Medical Innovation. <i>Health Affairs</i> , 2017 , 36, 1518	6.6	
24	Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. <i>Nature</i> , 2017 , 552, 194-199	47.1	294
23	Searching for Positive Side Effects of Common Drugs. <i>Trends in Pharmacological Sciences</i> , 2017 , 38, 111	12.7	12
22	Drug Repurposing for Terminal-Stage Cancer Patients. <i>American Journal of Public Health</i> , 2016 , 106, e3	4.8	1
21	The Raffles Dialogue on Human Wellbeing and Security. <i>The Lancet Global Health</i> , 2016 , 4, e92	11.9	2
20	Deubiquitinases (DUBs) and DUB inhibitors: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2015 , 25, 1191-1208	6.4	68
19	Low-Income Countries And Repurposed Drugs. <i>Health Affairs</i> , 2015 , 34, 2004	6.6	1
18	Diethyldithiocarbamate complexes with metals used as food supplements show different effects in cancer cells. <i>Journal of Applied Biomedicine</i> , 2014 , 12, 301-308	0.6	13
17	Linking the activity of bortezomib in multiple myeloma and autoimmune diseases. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 92, 61-70	6.7	15
16	A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. <i>Oncotarget</i> , 2013 , 4, 502-30	3.1	131
15	Proteasome inhibitors. <i>Progress in Molecular Biology and Translational Science</i> , 2012 , 109, 161-226	3.8	23
14	Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram). <i>Drug Discovery Today</i> , 2012 , 17, 409-12	8.3	65
13	Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012 , 12, 1184-92	3	51
12	Antabuse repurposing: We need more knowledge and wide international support. <i>International Journal of Cancer</i> , 2011 , 129, 1286-1287	7.2	3
11	The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib. <i>Current Pharmaceutical Design</i> , 2011 , 17, 1483-99	3.1	35
10	Antabuse (disulfiram) as a pilot case of nonprofit drug. <i>International Journal of Cancer</i> , 2010 , 127, 2486	7.2	4
9	Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways. <i>Human Reproduction</i> , 2009 , 24, 2967; author reply 2967-8	5.5	

8	Examination of Zolpidem effects on AhR- and PXR-dependent expression of drug-metabolizing cytochromes P450 in primary cultures of human hepatocytes. <i>Toxicology Letters</i> , 2009 , 191, 74-8	4.1	5
7	Failure of ditiocarb (diethyldithiocarbamate) therapy: was diet the reason?. <i>Current HIV Research</i> , 2009 , 7, 254	1.3	2
6	The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?. <i>Drug Discovery Today</i> , 2008 , 13, 716-22	8.3	62
5	Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 6256-8	7.8	163
4	TNF-alpha could be responsible for disulfiram-mediated hepatotoxicity. <i>Journal of Hepatology</i> , 2008 , 49, 865-6	3	2
3	Opposite effects of two zinc(II) dithiocarbamates on NF-kB pathway. <i>Nature Precedings</i> , 2007 ,		1
2	Symmetric Ni(II) dithiocarbamates with bidentate phosphines ligands. <i>Journal of Coordination Chemistry</i> , 2006 , 59, 911-919	1.5	14
1	Nickel(II) di(pentyl)dithiocarbamates with P ligands. <i>Journal of Coordination Chemistry</i> , 2003 , 56, 1123-1129		10